India's Biopharma Moment (Endiya Partners)

Summary

• India's bioeconomy grew from $10 B in 2014 to about $195 B in 2026, with a projection of nearly $300 B by 2033.p.10
• R&D costs now average $2.2B per asset globally.p.4
• India offers a 3x cost arbitrage, reaching Clinical Proof of Concept for <$50M versus $150M+ in the West.p.5
• The RDI Fund approved in July 2025 has a corpus of ₹1,00,000 crore (~$11B).p.15
• India has 2,500+ biotech startups and ~100 BioNEST incubators.p.19
• AbbVie's deal for ISB 2001 included $700M upfront and a deal value of $1.9B.p.23
• India accounts for roughly 20% of global generic volume and 40% of US generic prescriptions.p.10

Key insights

1. Asia has expanded its share of the global innovative pipeline to 43%.p.7
2. India supplies over 60% of global vaccine doses by volume.p.10
3. Biopharma SHAKTI was announced in the 2026-27 Union Budget with a ₹10,000 crore ($1B) outlay.p.15
4. The National Biopharma Mission launched in 2017 with an outlay of ₹1,500 crore, co-funded 50% by the World Bank.p.14
5. The efficacy waiver for biosimilars reduces the cost of bringing a biosimilar to market by 30%-50%.p.17
6. Only about 50 biotherapeutics companies have raised seed VC funding and about 20 have raised a Series A.p.19
7. Standard government grants of often ₹50L are insufficient for biologics development.p.28
8. The 45-day statutory clock is legally binding but the regulator's institutional machinery is still in initial stages.p.25